substantia nigra

The substantia nigra is located in the midbrain (mesencephalon) and is part of the basal ganglia circuitry. It has two main components: the pars compacta, which contains dopaminergic neurons that project to the striatum (caudate and putamen) via the nigrostriatal pathway, and the pars reticulata, which contains GABAergic neurons that serve as an output nucleus of the basal ganglia, similar to the globus pallidus interna.

Dopaminergic neurons in the pars compacta use neuromelanin, giving the substantia nigra its characteristic dark pigmentation grossly. These neurons modulate movement by facilitating the direct pathway (via D1 receptors) and inhibiting the indirect pathway (via D2 receptors) in the striatum, promoting smooth, voluntary movement.

In Parkinson's disease, there is progressive loss of dopaminergic neurons in the pars compacta, leading to decreased dopamine in the striatum. This results in the classic triad of resting tremor (pill-rolling), rigidity (cogwheel), and bradykinesia, often with postural instability (TRAP). Pathologically, Lewy bodies (eosinophilic intracytoplasmic inclusions composed of alpha-synuclein) are found in surviving neurons, and there is depigmentation of the substantia nigra grossly.

The substantia nigra is also relevant in other conditions: MPTP-induced parkinsonism (a toxin that selectively destroys dopaminergic neurons, historically from contaminated illicit drugs), and it's a target for treatments like levodopa/carbidopa (dopamine precursor), dopamine agonists, and MAO-B inhibitors (selegiline) which aim to restore dopaminergic signaling. Deep brain stimulation of the subthalamic nucleus or globus pallidus interna is used in advanced disease.

Understanding the substantia nigra's role helps explain why loss of dopamine leads to an imbalance favoring the indirect pathway, resulting in excessive inhibition of the thalamus and reduced excitatory input to the motor cortex, manifesting as hypokinetic movement disorders.